Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Aligning pharmaceutical innovation with medical need

Nature Medicine volume 13, pages 304–308 (2007)Cite this article

How can we make vaccines and medicines for major diseases that have been largely ignored? How can we get vaccines and medicines to populations that cannot afford them? A fundamental solution to these problems requires aligning three basic processes—innovation, incentive and access—so that they become mutually reinforcing. The present patent system provides incentives for innovation by enforcing product monopolies that permit sales at prices far above production cost. Industry has little financial incentive to develop products for diseases that mainly afflict the poor, and the poor cannot afford products that industry develops for wealthier customers. Two reforms could correct these disparities and benefit all stakeholders. First, open-access drug companies—fee-for-service sites within drug companies for collaborations among academics and biotechnology and pharmaceutical professionals, funded by users and government—would bring new ideas and expertise to the development of drugs independent of market drivers. Second, a patent track that rewards innovation in proportion to its impact on the global burden of disease would provide an incentive for pricing near the cost of production and commit government and business to improving health care delivery. Allying open access and traditional drug companies and offering a credit-assignment patent track alongside the monopoly-enforcement track would increase the number and accessibility of medical interventions, industry's therapeutic and geographic opportunities, and global health.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Alternative relationships among innovation, incentive and access.

References

  1. Pisano, G.P. Harv. Bus. Rev. 84, 114–124 (2006).

    PubMed  Google Scholar 

  2. Barton, J.H. & Emanuel, E.J. J. Am. Med. Assoc. 294, 2075–2082 (2005).

    Article  CAS  Google Scholar 

  3. Hubbard, T. & Love, J. PLoS Biol. 2, E52 (2004).

    Article  Google Scholar 

  4. Cuatrecasas, P. J. Clin. Invest. 116, 2837–2842 (2006).

    Article  CAS  Google Scholar 

  5. Dugger, C. New York Times A9, 1 December 2006.

    Google Scholar 

  6. Commission on Intellectual Property Rights, Innovation and Public Health (CIPI), World Health Organization <http://www.who.int/intellectualproperty/report/en/index.html> (2005).

  7. Pecoul, B., Chirac, P., Trouiller, P. & Pinel, J. J. Am. Med. Assoc. 281, 361–367 (1999).

    Article  CAS  Google Scholar 

  8. Chirac, P. & Torreele, E. Lancet 367, 1560–1561 (2006).

    Article  Google Scholar 

  9. Nathan, C. Nature 431, 899–902 (2004).

    Article  CAS  Google Scholar 

  10. Fox, J.L. Nat. Biotechnol. 24, 1521–1528 (2006).

    Article  CAS  Google Scholar 

  11. Katz, M.L., Mueller, L.V., Polyakov, M. & Weinstock, S.F. Nat. Biotechnol. 24, 1529–1531 (2006).

    Article  CAS  Google Scholar 

  12. Leaf, C. Fortune 149, 76–88 passim (2004).

    PubMed  Google Scholar 

  13. Sporn, M.B. Nat. Clin. Pract. Oncol. 3, 364–373 (2006).

    Article  Google Scholar 

  14. Lanjouw, J. Innovations 1, 108–140 (2006).

    Article  Google Scholar 

  15. Hollis, A. <http://econ.ucalgary.ca/fac-files/ah/drugprizes.pdf> (2005).

  16. Baker, D. <http://sippi.aaas.org/ipissues/publications/?res_id+434> (2004).

  17. Check, E. Nature 444, 412–413 (2006).

    Article  CAS  Google Scholar 

  18. Pogge, T. Metaphilosopy 36, 182–209 (2005).

    Article  Google Scholar 

  19. Centre for Applied Philosophy and Public Ethics. <http://www.who.int/public_hearing_phi/summary/15Nov06CAPPEpogge.pdf> (2006).

  20. Nwaka, S. & Hudson, A. Nat. Rev. Drug Discov. 5, 941–955 (2006).

    Article  CAS  Google Scholar 

  21. MacCoss, M. & Baillie, T.A. Science 303, 1810–1813 (2004).

    Article  CAS  Google Scholar 

  22. Clardy, J., Fischbach, M.A. & Walsh, C.T. Nat. Biotechnol. 24, 1541–1550 (2006).

    Article  CAS  Google Scholar 

  23. Fenical, W. & Jensen, P.R. Nat. Chem. Biol. 2, 666–673 (2006).

    Article  CAS  Google Scholar 

  24. Lewis, K. & Ausubel, F.M. Nat. Biotechnol. 24, 1504–1507 (2006).

    Article  CAS  Google Scholar 

  25. Walsh, C.T. et al. & Casadevall, A. et al. Treating Infectious Diseases in a Microbial World: Report of Two Workshops 1–63. (National Academies Press, Washington, DC, 2005).

    Google Scholar 

  26. Payne, D.J., Gwynn, M.N., Holmes, D.J. & Pompliano, D.L. Nat. Rev. Drug Discov. 6, 29–40 (2007).

    Article  CAS  Google Scholar 

  27. Alliance for the Prudent Use of Antibiotics. <http://www.tufts.edu/med/apua/> (2007).

  28. Sanders, B. <http://olpa.od.nih.gov/legislation/109/pendinglegislation/medicalinnovation.asp> (2005).

  29. Fisher, E.S. N. Engl. J. Med. 355, 1845–1847 (2006).

    Article  CAS  Google Scholar 

  30. Love, J. Bull. World Health Organ. 84, 408 (2006).

    Google Scholar 

  31. World Health Organization. <http://www.who.int/public_hearing_phi/en/> (2006).

  32. Renslo, A.R. & McKerrow, J.H. Nat. Chem. Biol. 2, 701–710 (2006).

    Article  CAS  Google Scholar 

  33. Nathan, C. & Goldberg, F.M. Nat. Rev. Drug Discov. 4, 887–891 (2005).

    Article  CAS  Google Scholar 

  34. Grabowski, H. http://www.econ.duke.edu/papers/other/grabowski/orphan-drug.pdf (2003).

  35. Kremer, M. & Glennerster, R. Strong Medicine: Creating Incentives for Pharmaceutical Research on Neglected Diseases 55–67 (Princeton University Press, Princeton, New Jersey, USA, 2004).

    Google Scholar 

  36. Danzon, P.M. & Towse, A. Int. J. Health Care Finance Econ. 3, 183–205 (2003).

    Article  Google Scholar 

  37. Outterson, K. Yale J. Health Policy Law Ethics 5, 193–291 (2005).

    PubMed  Google Scholar 

  38. Abramowicz, M. Vanderbilt Law Rev. 56, 114–236 (2003).

    Google Scholar 

  39. Kremer, M. Q. J. Econ. 113, 1137–1167 (1998).

    Article  Google Scholar 

  40. Lopez, A.D., Mathers, C.D., Ezzati, M., Jamison, D.T. & Murray, C.J.L., eds. Global Burden of Disease and Risk Factors (The World Bank and Oxford University Press, New York, 2006).

    Book  Google Scholar 

Download references

Acknowledgements

Thanks are due P. Davies, C. Leaf, M. Kurilla, S. Nwaka, T. Pogge, A. Simpson, M. Sporn, O. Vandal and T. von Schoen-Angerer for guidance to literature and critique of the manuscript.

Author information

Authors and Affiliations

  1. Carl Nathan is at the Weill Cornell Medical College, 1300 York Avenue, New York, New York 10021, USA. cnathan@med.cornell.edu,

    Carl Nathan

Authors
  1. Carl Nathan
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Nathan, C. Aligning pharmaceutical innovation with medical need. Nat Med 13, 304–308 (2007). https://doi.org/10.1038/nm0307-304

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0307-304

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing